iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Gland Pharma gets USFDA approval for blood pressure drug

4 Jun 2025 , 03:34 PM

Gland Pharma Limited’s share price gained as much as 3% in Wednesday’s intraday session after the company announced that it has received approval from the United States Food and Drug Administration (USFDA) for a blood pressure treatment drug.

At around 3.19 PM, Gland Pharma was trading 2.25% higher at ₹1,624.60 per piece, against the previous close of ₹1,588.90 on NSE. The counter touched an intraday high and low of ₹1,638, and ₹1,588.40, respectively.

In its filing with the bourses, the company stated that it has received approval from the US drug regulator for Angiotensin II Acetate injection, 2.5 mg/mL. As per the company, this drug can be used for treatment of blood pressure in adults with septic or other distributive shock.

The approved drug is the generic equivalent of GIAPREZA, a drug developed by La Jolla Pharma LLC. 

The new drug can be used for the treatment of increasing blood pressure in adults who experience septic or other forms of distributive shock, stated the company.

Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.

Additionally, Gland Pharma has the exclusive First-To-File (FTF) status for stated products. Hence, Gland Pharma has 180 days of generic drug exclusivity in the US market.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Gland Pharma
  • Gland Pharma news
  • Gland Pharma Updates
  • Gland Pharma USFDA
  • Gland Pharma USFDA Approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.